Skip to main content Help with accessibility Skip to main navigation

Recommendations

Coronavirus guidance

Guidance to support primary care prescribers and pharmacists is available from the MLCSU Coronavirus guidance resource page. Links are provided to national resources and regional documents produced by MLCSU, RDTC, and SPS for use by Pan Mersey APC, LSCMMG, and GMMMG.

The list of resources will be updated as new material becomes available so please check back regularly for updates.

The Pan Mersey APC supports the use of COVID-specific guidance issued by NICE, and NHS England and NHS Improvement. During the COVID pandemic this will supersede any APC advice. In the absence of any COVID-specific advice then the usual Pan Mersey guidance and RAG rating will still apply unless otherwise indicated.

This section contains a list of the policy recommendations of the Pan Mersey Area Prescribing Committee.

Reviews of the new medicines have been conducted by our pharmacists using a number of resources including National Institute for Health and Clinical Excellence (NICE) which is a Special health Authority (SHA) set up in 1999. It is used to give advice to the NHS on best clinical practice including the clinical and cost effectiveness of drugs and other treatments.

Definitions and Criteria for Categorisation of Medicines

Documents

Date Added: 25 - Sep - 2019

The Pan Mersey Area Prescribing Committee recommends the prescribing of RANIBIZUMAB intravitreal injection (Lucentis®), by ophthalmologists only, for the treatment of visual impairment secondary to choroidal neovascularisation (CNV) in conditions not covered by NICE technology appraisals.

Static

Body System:
Date Added: 19 - Dec - 2019

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of RANIBIZUMAB solution for injection (Lucentis®) for the treatment of proliferative diabetic retinopathy.

Body System:
Date Added: 31 - Jul - 2019

The Pan Mersey Area Prescribing Committee does not recommend the prescribing of Rasburicase powder and solvent for concentrate for solution for infusion (Fasturtec®▼) for the “off label” treatment of severe, refractory, tophaceous gout resistant to xanthine oxidase inhibitors (allopurinol & febuxostat) and uricosuric agents (benzbromarone) or for whom these drugs are contraindicated.

Static

Body System:
Date Added: 26 - Jul - 2017

The Pan Mersey Area Prescribing Committee recommends RIFAXIMIN 550mg tablets (Targaxan®), following specialist initiation, as an option for reducing the recurrence of overt hepatic encephalopathy in people aged 18 years or older in accordance with NICE TA 337.

Static

Date Added: 25 - Sep - 2019

The Pan Mersey Area Prescribing Committee recommends the prescribing of RISANKIZUMAB solution for injection (Skyrizi®▼), by specialists only, for moderate to severe plaque psoriasis in accordance with NICE TA596.

Body System:
Date Added: 15 - Nov - 2017

NHS England specialised commissining resources: the clinical reference group responsible for specialised rheumatology has published a commissioning policy that defines access to a particular service for a cohort of patients.

Body System:
Date Added: 15 - Nov - 2017

NHS England specialised commissining resources: the clinical reference group responsible for specialised rheumatology has published a commissioning policy that defines access to a particular service for a cohort of patients.

Body System:
Date Added: 26 - Jun - 2019

RITUXIMAB (Truxima®▼, Rixathon®▼)The Pan Mersey Area Prescribing Committee recommends the prescribing of rituximab by specialists only, for immune (idiopathic) thrombocytopenic purpura before romiplostin and eltrombopag.

Date Added: 24 - May - 2017

The Pan Mersey Area Prescribing Committee recommends the prescribing of rituximab infusion for rheumatoid arthritis in accordance with NICE TA195 and in accordance with the Mersey Rheumatoid Arthritis Biologics Pathway.  Treatment should be initiated and supervised by a rheumatologist.

Static

Body System:
Date Added: 24 - May - 2017

The Pan Mersey Area Prescribing Committee recommends the prescribing of Rivaroxaban 2.5mg tablets (Xarelto®▼) following specialist initiation for preventing adverse outcomes after acute management of acute coronary syndrome in accordance with NICE TA335.

Static

Body System:
Date Added: 28 - Nov - 2019

The Pan Mersey Area Prescribing Committee recommends the prescribing of RIVAROXABAN 2.5mg tablets (Xarelto®▼) plus aspirin, for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events, in accordance with NICE TA607.

Body System:
Date Added: 31 - Jul - 2019

The Pan Mersey Area Prescribing Committee recommends the prescribing of ROFLUMILAST tablets (Daxas®▼) following specialist recommendation as an add-on to bronchodilator therapy, for treating severe chronic obstructive pulmonary disease in adults with chronic bronchitis (in accordance with NICE TA461).

Static

Body System:
Date Added: 31 - Jan - 2019

The Pan Mersey Area Prescribing Committee recommends the prescribing of ROMIPLOSTIM SC injection (Nplate®), by Haematologists only, for chronic immune (idiopathic) thrombocytopenic purpura (ITP) in accordance with NICE TA221.

Date Added: 06 - May - 2020

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of ROMOSOZUMAB solution for injection (EVENITY®▼) for treatment of severe osteoporosis in postmenopausal women.

Body System:
Date Added: 31 - Jan - 2018

The Pan Mersey Area Prescribing Committee recommends the prescribing of ROSUVASTATIN TABLETS tablets ONLY where no other statin is suitable.

Static

Body System:
Date Added: 26 - Jun - 2019

The Pan Mersey Area Prescribing Committee does not recommend the prescribing of RUBEFACIENTS (excluding topical NSAIDS and capsaicin).

Body System: